TScan Therapeutics (TCRX) Payables (2020 - 2026)
TScan Therapeutics (TCRX) posted quarterly Payables of $2.3 million for Q1 2026, down 53.62% year-over-year from $5.0 million in Q1 2025, and up 85.58% quarter-over-quarter from $1.2 million in Q4 2025.
TScan Therapeutics (TCRX) Payables (2020 - 2026) Analysis & Trends
TScan Therapeutics (TCRX) has reported Payables for 7 consecutive years, with $2.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Payables fell 53.62% year-over-year to $2.3 million; the TTM figure through Mar 2026 stood at $2.3 million (down 53.62% YoY), while the FY2025 annual figure was $1.2 million, down 70.99% from the prior year.
- Payables advanced to $2.3 million in Q1 2026 per TCRX's latest filing, from $1.2 million in the prior quarter.
- Across five years, Payables topped out at $6.4 million in Q3 2025 and bottomed at $1.2 million in Q4 2025.
- Historically, Payables has averaged $3.3 million across 5 years, with a median of $3.1 million in 2022.
- On a YoY basis, Payables climbed as much as 133.91% in 2025 and fell as far as 70.99% in 2025.
- TScan Therapeutics' Payables stood at $2.9 million in 2022, then declined by 18.48% to $2.4 million in 2023, then soared by 80.2% to $4.3 million in 2024, then sank by 70.99% to $1.2 million in 2025, then jumped by 85.58% to $2.3 million in 2026.
- Business Quant data shows TCRX's Payables at $2.3 million in Q1 2026, $1.2 million in Q4 2025, and $6.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 35.57 Mn |
| 10 | TScan Therapeutics | 100.62 Mn | 100.62 Mn | - | 3.12 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.12 Mn |
| Mar 31, 2026 | 2.30 Mn |
| Dec 31, 2025 | 1.24 Mn |
| Sep 30, 2025 | 6.35 Mn |
| Jun 30, 2025 | 4.54 Mn |
| Mar 31, 2025 | 4.97 Mn |
| Dec 31, 2024 | 4.28 Mn |
| Sep 30, 2024 | 3.65 Mn |
| Jun 30, 2024 | 3.11 Mn |
| Mar 31, 2024 | 2.12 Mn |
| Dec 31, 2023 | 2.37 Mn |
| Sep 30, 2023 | 3.20 Mn |
| Jun 30, 2023 | 3.39 Mn |
| Mar 31, 2023 | 2.77 Mn |
| Dec 31, 2022 | 2.91 Mn |
| Sep 30, 2022 | 2.71 Mn |
| Jun 30, 2022 | 3.10 Mn |
| Mar 31, 2022 | 2.89 Mn |
| Dec 31, 2021 | 1.77 Mn |
| Sep 30, 2021 | 5.07 Mn |